Benzinga | Mar 11, 2021 08:37AM EST

UBS Initiates Coverage On Biohaven Pharma Hldgs with Buy Rating, Announces Price Target of $108

UBS analyst Esther Rajavelu initiates coverage on Biohaven Pharma Hldgs (NYSE:BHVN) with a Buy rating and announces Price Target of $108.